Keio Innovation Initiative has invested in Himuka AM Pharma, a venture company engaged in research and development of novel drug discovery seeds of improved adrenomedullin, from a fund managed by our company.
Himuka AM Pharma is a venture company engaged in drug discovery and development based on the diverse physiological activities of adrenomedullin (AM), a bioactive peptide discovered at the University of Miyazaki Faculty of Medicine and currently undergoing basic and clinical research.
The company is currently developing a novel drug for intractable inflammatory bowel disease with a development support grant from the Japan Agency for Medical Research and Development’s “Drug Discovery Support Promotion Program – Pre-designation Commercialization Support Program for Orphan Drugs”, in which Keio University School of Medicine is also collaborating.